PRLD Crosses Above Average Analyst Target
July 17, 2024 at 08:57 AM EDT
In recent trading, shares of Prelude Therapeutics Inc (PRLD) have crossed above the average analyst 12-month target price of $5.80, changing hands for $6.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..
